GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

Clinical trial NCT06948981 · RECRUITING

Trial details

NCT number: NCT06948981
Sponsor: Grit Biotechnology
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Hematological Malignancy (Leukemia- Lymphoma)

Start date: 2025-04-18
Primary completion: 2028-04-17
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.